FDA authorizes additional COVID-19 vaccine dose for immunocompromised
The U.S. Food and Drug Administration amended the emergency use authorizations for both the Pfizer-BioNTech and the Moderna novel coronavirus (COVID-19) vaccinations to allow for the use of an additional dose in certain immunocompromised individuals, specifically solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise, according to an announcement made late last week by the agency.
People who are immunocompromised in a manner like those who have undergone solid organ transplantation have a reduced ability to fight infections and other diseases, and they are especially vulnerable to infections, including COVID-19, the agency said.
The FDA evaluated information on the use of a third dose of the Pfizer-BioNTech or Moderna vaccines in these individuals and determined that the administration of third vaccine doses may increase protection in this population.
These patients should be counseled to maintain physical precautions to help prevent COVID-19. In addition, close contacts of immunocompromised persons should get vaccinated, as appropriate for their health status, to provide increased protection to their loved ones.